Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03488693 · ClinicalTrials.gov registry record · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,140
- Enrollment target
- 20
- Study locations
NCT03488693: Recruiting Phase 3 study of Breast Cancer, sponsored by Canadian Cancer Trials Group.
NCT03488693 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 2,140 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03488693, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Primary Outcome
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
Conditions Studied
Interventions
- RADIATION Radiation
- OTHER No Radiation
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Bellflower - Bellflower
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- City of Hope Corona - Corona
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
- UC San Diego Health System - Encinitas - Encinitas
- Fresno Cancer Center - Fresno
- City of Hope at Irvine Lennar - Irvine
- UC San Diego Moores Cancer Center - La Jolla
- City of Hope Antelope Valley - Lancaster
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Providence Queen of The Valley - Napa
- Kaiser Permanente Oakland-Broadway - Oakland
Arizona
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,140 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
What NCT03488693 shows while recruiting
NCT03488693 is an interventional study that assigns participants to a tested intervention. Its 2,140 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT03488693 names 20 study sites across 4 states, led by California, Arizona, Alaska.
Frequently Asked Questions
What is clinical trial NCT03488693 about?
NCT03488693 is a clinical study titled "Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer". The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer ...
What is the current status of trial NCT03488693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,140 participants. The study started on 2018-10-16. Estimated completion is 2027-12-30.
What conditions does trial NCT03488693 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03488693?
The interventions under investigation include: Radiation (RADIATION), No Radiation (OTHER).
Who is sponsoring clinical trial NCT03488693?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03488693 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03488693's enrollment target sits among peer trials
2,140 66th of 1224 higher than 1,159 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI